Drug Profile
Research programme: radioprotectants - RxBio
Alternative Names: DBIBB; Rx 100; RX100Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator University of Tennessee
- Developer RxBio
- Class Benzoic acids; Small molecules
- Mechanism of Action Apoptosis inhibitors; Lysophosphatidic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastric damage; Radiation injuries
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gastric-damage in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Radiation-injuries in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Radiation-injuries in USA (SC)